Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 1/20 | 0.57 |
| ▸ | RHOA | P61586 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 8/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76266 | 1.00 | RHOC (0.57) | RHOCRHOAF10F2MAPT | |
| SCHEMBL76265 | 1.00 | RHOC (0.57) | RHOCRHOAF10F2MAPT | |
| SCHEMBL27713501 | 0.91 | F10 (0.56) | RHOCRHOAF10ALDH1A1HPGD | |
| SCHEMBL13725967 | 0.90 | F10 (0.53) | RHOCRHOAF10POLB | |
| SCHEMBL77021 | 0.85 | ALDH1A1 (0.56) | RHOCRHOAF10F2ALDH1A1 | |
| SCHEMBL77020 | 0.85 | ALDH1A1 (0.56) | RHOCRHOAF10F2ALDH1A1 | |
| SCHEMBL76925 | 0.84 | F10 (0.57) | RHOCRHOAF10MAPTALDH1A1 | |
| SCHEMBL76890 | 0.84 | F10 (0.57) | RHOCRHOAF10MAPTALDH1A1 | |
| SCHEMBL76889 | 0.84 | F10 (0.57) | RHOCRHOAF10MAPTALDH1A1 | |
| SCHEMBL5605147 | 0.83 | F10 (0.49) | F10F2MAPTHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | claimed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | claimed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | RHOC 3122/4885RHOA 2693/4885F10 5/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | RHOC 2392/4885RHOA 1393/4885F10 22/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | RHOC 3122/4885RHOA 2693/4885F10 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.